STOCK TITAN

Vanguard realigns reporting; reports 0 shares of Sarepta (SRPT)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Sarepta Therapeutics Inc ownership filing shows that The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing notes an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, causing certain Vanguard subsidiaries to report separately.

Positive

  • None.

Negative

  • None.

Insights

Neutral technical update on reporting structure; no ownership change.

The filing documents that The Vanguard Group holds 0 shares and 0% ownership of Sarepta common stock. The primary content is a reporting realignment under SEC Release No. 34-39538 that disaggregates ownership reporting across Vanguard entities.

Cash‑flow treatment and trading intent are not stated; subsequent filings from Vanguard entities may disclose holdings if any are reported separately.






803607100

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does The Vanguard Group report for SRPT ownership?

The Vanguard Group reports 0 shares beneficially owned of Sarepta common stock, representing 0% of the class. The filing records ownership figures in Item 4 showing zero shares and zero voting or dispositive power.

Why does Vanguard mention an internal realignment in the 13G/A?

Vanguard cites an internal realignment effective January 12, 2026 and SEC Release No. 34-39538, stating certain subsidiaries will report beneficial ownership separately. This explains disaggregation of prior holdings across Vanguard entities rather than a single Vanguard aggregate report.

Does this filing indicate any purchases or sales of SRPT by Vanguard?

No. The filing lists 0 shares beneficially owned and zero voting and dispositive power. It does not describe purchases, sales, or transaction dates; it is a reporting update tied to organizational reporting changes.

Who signed the Schedule 13G/A for Vanguard and when?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with the signature date of 03/27/2026. The signature block appears at the end of the filing and certifies the reported ownership details.

Will other Vanguard entities report SRPT holdings separately now?

Yes. The filing states certain Vanguard subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538 after the January 12, 2026 realignment. Specific subsidiary reports are not included in this excerpt.
Sarepta Therapeutics Inc

NASDAQ:SRPT

View SRPT Stock Overview

SRPT Rankings

SRPT Latest News

SRPT Latest SEC Filings

SRPT Stock Data

2.28B
99.57M
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE